FDA panel backs Vivus obesity drug Qnexa

FDA panel backs Vivus obesity drug Qnexa

Original Article: FDA panel backs Vivus obesity drug Qnexa

 Channels 75 Associated Channels

• Obesity

  Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dic...

• Obesity and the Metabolic Syndrome

• Drug Approvals

  In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in e...

• Bcl-2 Antisense Drug

• CMV Antisense Drug

• Drug Discovery - news, views, blogs and reports

  In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are discovered and/or designed. In the past most drugs have been discovered either by identi...

• Minimizing drug interactions

• Adverse drug effects

• Adverse Drug Reactions

• Drug Delivery - news, views, blogs

  Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  Drug delivery technologies are patent protected formulat...

Associated Content for this Article

• View Related Companies
• View Related Events
• View Related Clinical Trials
• View Related PubMed Articles
• View Related Medications

Latest Biotechnology, Pharmaceutical and Healthcare News

Searches Linking to this Page

qnexa, qnexa, Qnexa, qnexa, qnexa, qnexa, qnexa fda, qnexa, qnexa, qnexa, diet drugs awaiting approval, qnexa, qnexa, qnexa